4.66
Goodrx Holdings Inc stock is traded at $4.66, with a volume of 1.48M.
It is up +2.19% in the last 24 hours and down -3.52% over the past month.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
See More
Previous Close:
$4.56
Open:
$4.6
24h Volume:
1.48M
Relative Volume:
1.14
Market Cap:
$1.79B
Revenue:
$775.09M
Net Income/Loss:
$-58.68M
P/E Ratio:
-35.14
EPS:
-0.1326
Net Cash Flow:
$64.06M
1W Performance:
-5.67%
1M Performance:
-3.52%
6M Performance:
-39.64%
1Y Performance:
-35.46%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Name
Goodrx Holdings Inc
Sector
Industry
Phone
(855) 268-2822
Address
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GDRX
Goodrx Holdings Inc
|
4.66 | 1.79B | 775.09M | -58.68M | 64.06M | -0.1326 |
![]()
VEEV
Veeva Systems Inc
|
233.46 | 37.90B | 2.75B | 714.14M | 1.09B | 4.33 |
![]()
SOLV
Solventum Corp
|
74.01 | 12.80B | 8.26B | 66.00M | 1.17B | 0.3682 |
![]()
DOCS
Doximity Inc
|
64.30 | 12.07B | 516.85M | 174.11M | 217.38M | 0.87 |
![]()
HQY
Healthequity Inc
|
95.78 | 8.30B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
TEM
Tempus Ai Inc
|
45.50 | 7.84B | 640.44M | -743.28M | -206.93M | -11.29 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-24 | Initiated | Mizuho | Neutral |
Aug-09-24 | Upgrade | Raymond James | Outperform → Strong Buy |
May-23-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
May-16-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-25-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
Feb-26-24 | Initiated | Leerink Partners | Outperform |
Jan-02-24 | Downgrade | BofA Securities | Buy → Underperform |
Aug-10-23 | Upgrade | DA Davidson | Neutral → Buy |
Jul-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
Dec-01-22 | Initiated | Citigroup | Buy |
Nov-04-22 | Upgrade | JP Morgan | Underweight → Neutral |
Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-07-22 | Initiated | Truist | Hold |
Aug-12-22 | Initiated | DA Davidson | Neutral |
Jun-10-22 | Downgrade | Goldman | Buy → Neutral |
Jun-06-22 | Resumed | BofA Securities | Buy |
Jun-01-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-10-22 | Downgrade | Evercore ISI | Outperform → In-line |
May-10-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
May-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-10-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Apr-11-22 | Initiated | Wells Fargo | Equal Weight |
Apr-07-22 | Initiated | Guggenheim | Buy |
Apr-01-22 | Resumed | Credit Suisse | Neutral |
Mar-15-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Mar-01-22 | Reiterated | Barclays | Overweight |
Mar-01-22 | Reiterated | BofA Securities | Neutral |
Mar-01-22 | Downgrade | Cowen | Outperform → Market Perform |
Mar-01-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Mar-01-22 | Reiterated | Evercore ISI | Outperform |
Mar-01-22 | Reiterated | Goldman | Buy |
Mar-01-22 | Reiterated | JP Morgan | Underweight |
Mar-01-22 | Reiterated | RBC Capital Mkts | Outperform |
Mar-01-22 | Reiterated | SVB Leerink | Outperform |
Jan-07-22 | Initiated | Goldman | Buy |
Dec-21-21 | Initiated | Stephens | Overweight |
Dec-02-21 | Initiated | Jefferies | Buy |
Aug-31-21 | Upgrade | Barclays | Equal Weight → Overweight |
Aug-13-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-28-21 | Initiated | Robert W. Baird | Neutral |
Apr-06-21 | Resumed | Evercore ISI | Outperform |
Jan-25-21 | Initiated | Guggenheim | Buy |
Nov-19-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-19-20 | Initiated | Barclays | Equal Weight |
Oct-19-20 | Initiated | BofA Securities | Neutral |
Oct-19-20 | Initiated | Citigroup | Buy |
Oct-19-20 | Initiated | Cowen | Outperform |
Oct-19-20 | Initiated | Credit Suisse | Outperform |
Oct-19-20 | Initiated | Deutsche Bank | Hold |
Oct-19-20 | Initiated | Goldman | Neutral |
Oct-19-20 | Initiated | JP Morgan | Neutral |
Oct-19-20 | Initiated | Morgan Stanley | Overweight |
Oct-19-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-19-20 | Initiated | SVB Leerink | Outperform |
Oct-19-20 | Initiated | UBS | Buy |
View All
Goodrx Holdings Inc Stock (GDRX) Latest News
GoodRx Holdings, Inc. (GDRX): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
GoodRx Holdings, Inc. (GDRX): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Shareholders of GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Wells Fargo & Company Cuts GoodRx (NASDAQ:GDRX) Price Target to $8.00 - Defense World
Levi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineGDRX - ACCESS Newswire
GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Call Transcript - MSN
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc.(GDRX) Shareholders - ACCESS Newswire
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts - Benzinga
Investors who lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class ActionGDRX - ACCESS Newswire
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Decoding GoodRx Holdings Inc (GDRX): A Strategic SWOT Insight - GuruFocus.com
GoodRx Holdings Inc (GDRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
GoodRx Holdings Reports Strong 2024 Financial Results - TipRanks
GoodRx Earnings Call: Growth Amid Challenges - TipRanks
Citi raises GoodRx stock target to $6.75, maintains buy rating By Investing.com - Investing.com South Africa
GoodRx Holdings IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
Citi raises GoodRx stock target to $6.75, maintains buy rating - Investing.com
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics - MSN
Raymond James Reiterates Strong Buy Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider.com
GoodRx Holdings Inc. (GDRX) PT Raised to $6.75 at Citi - StreetInsider.com
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales - Benzinga
GoodRx shares rise on upbeat Q1 guidance despite Q4 miss By Investing.com - Investing.com Australia
Earnings call transcript: GoodRx Q4 2024 misses EPS forecast, stock rises - Investing.com
GoodRx Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Here's What Key Metrics Tell Us About GoodRx (GDRX) Q4 Earnings - Yahoo Finance
GoodRx Q4 Adjusted Earnings, Revenue Rise; Q1, 2025 Revenue Guidance Issued - Marketscreener.com
GoodRx Reports Fourth Quarter and Full Year 2024 Results - 01Net
GoodRx Holdings Sees Increased Revenue In Q1, Full YearUpdate - Nasdaq
GOODRX Earnings Results: $GDRX Reports Quarterly Earnings - Nasdaq
BRIEF-GoodRx Holdings Q4 Adjusted Net Income USD 34.7 Million Vs. IBES Estimate USD 37.4 Million - TradingView
GoodRx Holdings, Inc. (GDRX) Misses Q4 EPS by 1c ; Offers Guidance - StreetInsider.com
GoodRx Holdings, Inc. Q4 and Full Year 2024 Financial Results - TradingView
GoodRx (NASDAQ:GDRX) Misses Q4 Revenue Estimates - The Globe and Mail
GoodRx Earnings: What To Look For From GDRX By Stock Story - Investing.com Canada
GoodRx Earnings: What To Look For From GDRX - The Globe and Mail
GoodRx Holdings Inc (GDRX) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
GoodRx’s SWOT analysis: prescription savings leader faces pharmacy headwinds - Investing.com
GoodRx Holdings Inc expected to post earnings of 10 cents a shareEarnings Preview - TradingView
GoodRx Target of Unusually High Options Trading (NASDAQ:GDRX) - Defense World
GoodRx Holdings: Hold Rating Amid Leadership Changes and Modest Growth Expectations - TipRanks
Truist Securities Reiterates Hold Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 21, 2024 in GoodRx LawsuitGDRX - ACCESS Newswire
GDRX DEADLINE ALERT: Bernstein Liebhard LLP Reminds GoodRx Holdings, Inc. Investors of Upcoming Deadline - ACCESS Newswire
GoodRx (GDRX) to Release Quarterly Earnings on Thursday - Defense World
Scott Wagner Appointed to GoodRx Board of Directors - The Healthcare Technology Report.
Goodrx Holdings Inc Stock (GDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):